EP2060270A3 - Fibroblasten-Wachstumsfaktorrezeptor-1-Inhibitoren und Behandlungsverfahren damit - Google Patents
Fibroblasten-Wachstumsfaktorrezeptor-1-Inhibitoren und Behandlungsverfahren damit Download PDFInfo
- Publication number
- EP2060270A3 EP2060270A3 EP08020599A EP08020599A EP2060270A3 EP 2060270 A3 EP2060270 A3 EP 2060270A3 EP 08020599 A EP08020599 A EP 08020599A EP 08020599 A EP08020599 A EP 08020599A EP 2060270 A3 EP2060270 A3 EP 2060270A3
- Authority
- EP
- European Patent Office
- Prior art keywords
- fgfr
- treatment
- growth factor
- factor receptor
- fibroblast growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51225503P | 2003-10-16 | 2003-10-16 | |
EP04796034A EP1680140B1 (de) | 2003-10-16 | 2004-10-18 | Fibroblasten-wachstumsfaktor-1-hemmer und behandlungsverfahren dafür |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04796034A Division EP1680140B1 (de) | 2003-10-16 | 2004-10-18 | Fibroblasten-wachstumsfaktor-1-hemmer und behandlungsverfahren dafür |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2060270A2 EP2060270A2 (de) | 2009-05-20 |
EP2060270A3 true EP2060270A3 (de) | 2009-12-09 |
Family
ID=34465334
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04796034A Not-in-force EP1680140B1 (de) | 2003-10-16 | 2004-10-18 | Fibroblasten-wachstumsfaktor-1-hemmer und behandlungsverfahren dafür |
EP08020599A Withdrawn EP2060270A3 (de) | 2003-10-16 | 2004-10-18 | Fibroblasten-Wachstumsfaktorrezeptor-1-Inhibitoren und Behandlungsverfahren damit |
EP10162585A Withdrawn EP2229955A1 (de) | 2003-10-16 | 2004-10-18 | Fibroblasten-Wachstumsfaktor-Rezeptor-1-Hemmer und Behandlungsverfahren, die diese verwenden |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04796034A Not-in-force EP1680140B1 (de) | 2003-10-16 | 2004-10-18 | Fibroblasten-wachstumsfaktor-1-hemmer und behandlungsverfahren dafür |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10162585A Withdrawn EP2229955A1 (de) | 2003-10-16 | 2004-10-18 | Fibroblasten-Wachstumsfaktor-Rezeptor-1-Hemmer und Behandlungsverfahren, die diese verwenden |
Country Status (13)
Country | Link |
---|---|
US (2) | US20070274981A1 (de) |
EP (3) | EP1680140B1 (de) |
JP (1) | JP4686465B2 (de) |
AT (1) | ATE506077T1 (de) |
CA (2) | CA2542638A1 (de) |
CY (1) | CY1111479T1 (de) |
DE (1) | DE602004032370D1 (de) |
DK (1) | DK1680140T3 (de) |
ES (1) | ES2361917T3 (de) |
PL (1) | PL1680140T3 (de) |
PT (1) | PT1680140E (de) |
SI (1) | SI1680140T1 (de) |
WO (1) | WO2005037235A2 (de) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US20050282733A1 (en) * | 2002-06-27 | 2005-12-22 | Prins Johannes B | Differentiation modulating agents and uses therefor |
PT1680140E (pt) | 2003-10-16 | 2011-05-31 | Imclone Llc | Inibidores do receptor-1 do factor de crescimento de fibroblastos e m?todos de tratamento destes |
JP4890255B2 (ja) * | 2003-11-07 | 2012-03-07 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 改良された薬物特性を有するキノリノン化合物の薬学的に受容可能な塩 |
WO2006011686A1 (ja) * | 2004-07-30 | 2006-02-02 | Japan Tobacco Inc. | C型肝炎ウイルス(hcv)の細胞感染を阻害する化合物のスクリーニング方法 |
EP1882475A1 (de) * | 2006-07-26 | 2008-01-30 | Novartis AG | Methoden zur Behandlung von Erkrankungen, die durch den Fibroblastwachstumsfaktorrezeptor vermittelt werden |
CA2701128A1 (en) * | 2007-10-01 | 2009-04-09 | Isis Pharmaceuticals, Inc. | Antisense modulation of fibroblast growth factor receptor 4 expression |
JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
JOP20190083A1 (ar) | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
FR2933702A1 (fr) * | 2008-07-08 | 2010-01-15 | Sanofi Aventis | Antagonistes specifiques du recepteur fgf-r4 |
EP2358749B1 (de) | 2008-10-10 | 2018-07-18 | Amgen, Inc | Fgf21-mutanten und ihre verwendungen |
MX347291B (es) * | 2009-03-20 | 2017-04-17 | Amgen Inc | Inmunoglobulinas portadoras y usos de las mismas. |
US20120058116A1 (en) * | 2009-04-24 | 2012-03-08 | Andrew Beaton | Fgfr1c antibody combinations |
DK3248610T3 (da) | 2009-05-05 | 2024-01-15 | Amgen Inc | Fgf21-mutanter og anvendelser deraf |
AU2010246038A1 (en) | 2009-05-05 | 2011-12-01 | Amgen Inc. | FGF21 mutants and uses thereof |
EP2443145A1 (de) | 2009-06-17 | 2012-04-25 | Amgen, Inc | Chimäre fgf19-polypeptide und ihreverwendung |
BR112012007137A2 (pt) | 2009-09-30 | 2015-09-15 | Harvard College | metodos para modulacao da autofagia por meio da modulacao de produtos genicos inibidores da autofagia |
AU2010326024A1 (en) | 2009-12-02 | 2012-07-05 | Amgen Inc. | Binding proteins that bind to human FGFR1c, human beta-Klotho and both human FGFR1c and human beta-Klotho |
AU2014250730B2 (en) * | 2009-12-07 | 2016-10-13 | Amgen Inc. | Human antigen binding proteins that bind beta-Klotho, FGF receptors and complexes thereof |
UA109888C2 (uk) * | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
EP2558497A2 (de) | 2010-04-15 | 2013-02-20 | Amgen Inc. | Menschlicher fgf-rezeptor und beta-klotho-bindeproteine |
WO2012015674A1 (en) | 2010-07-26 | 2012-02-02 | Eli Lilly And Company | THERAPEUTIC USES OF AN FGFR1c ANTIBODY |
EA201370076A1 (ru) | 2010-09-22 | 2013-08-30 | Амген Инк. | Иммуноглобулины-переносчики и их применение |
SG10201602874VA (en) | 2010-12-15 | 2016-05-30 | Kek High Energy Accelerator | Protein production method |
RU2440142C1 (ru) * | 2011-02-07 | 2012-01-20 | Общество С Ограниченной Ответственностью "Онкомакс" | Антитело, останавливающее или замедляющее рост опухоли (варианты), способ подавления роста опухоли, способ диагностики злокачественных образований |
SG185832A1 (en) * | 2011-05-10 | 2012-12-28 | Agency Science Tech & Res | Fgfr1 antibodies and treatment of cancer |
CN103596983B (zh) * | 2011-04-07 | 2016-10-26 | 霍夫曼-拉罗奇有限公司 | 抗fgfr4抗体及使用方法 |
CN103596980B (zh) * | 2011-05-16 | 2017-08-08 | 霍夫曼-拉罗奇有限公司 | Fgfr1激动剂及使用方法 |
CN107936121B (zh) | 2011-05-16 | 2022-01-14 | 埃泰美德(香港)有限公司 | 多特异性fab融合蛋白及其使用方法 |
EP2721156B1 (de) | 2011-06-16 | 2016-12-21 | Ionis Pharmaceuticals, Inc. | Antisense-modulierung der expression des fibroblastenwachstumsfaktor-rezeptors 4 |
US20140294820A1 (en) * | 2011-06-24 | 2014-10-02 | University Of Miami | Fibroblast growth factor receptor inhibition for the treatment of disease |
EP2748197A2 (de) | 2011-08-26 | 2014-07-02 | Merrimack Pharmaceuticals, Inc. | Fc-bispezifische tandem-antikörper |
CN105246511A (zh) | 2013-03-06 | 2016-01-13 | 豪夫迈·罗氏有限公司 | 治疗和预防癌症药物抗性的方法 |
KR20150143458A (ko) | 2013-03-06 | 2015-12-23 | 메리맥 파마슈티컬즈, 인크. | 항-C-MET 탠덤 Fc 이중특이적 항체 |
SI3027651T1 (sl) | 2013-08-01 | 2019-05-31 | Five Prime Therapeutics, Inc. | Afukozilirana protitelesa proti fgfr2iiib |
TWI728373B (zh) | 2013-12-23 | 2021-05-21 | 美商建南德克公司 | 抗體及使用方法 |
WO2015148708A1 (en) | 2014-03-25 | 2015-10-01 | Regeneron Pharmaceuticals, Inc. | Fgf21 receptor agonists and uses thereof |
US20230190750A1 (en) | 2014-06-13 | 2023-06-22 | Genentech, Inc. | Methods of treating and preventing cancer drug resistance |
KR20170128234A (ko) | 2015-01-16 | 2017-11-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | Ror1에 특이적인 항체 및 키메라 항원 수용체 |
CN107667092B (zh) * | 2015-03-25 | 2021-05-28 | 诺华股份有限公司 | 作为fgfr4抑制剂的甲酰化n-杂环衍生物 |
EP3371217A1 (de) | 2015-11-08 | 2018-09-12 | H. Hoffnabb-La Roche Ag | Screening-verfahren für multispezifische antikörper |
RU2021107536A (ru) | 2015-11-23 | 2021-07-02 | Файв Прайм Терапьютикс, Инк. | Ингибиторы fgfr2 отдельно или в комбинации с иммуностимулирующими агентами в лечении рака |
MA43416A (fr) | 2015-12-11 | 2018-10-17 | Regeneron Pharma | Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3 |
JP7029401B2 (ja) | 2016-02-02 | 2022-03-03 | フレッド ハッチンソン キャンサー リサーチ センター | 抗ror1抗体およびその使用 |
WO2017157305A1 (en) | 2016-03-15 | 2017-09-21 | Generon (Shanghai) Corporation Ltd. | Multispecific fab fusion proteins and use thereof |
WO2018095932A1 (en) | 2016-11-22 | 2018-05-31 | Merck Patent Gmbh | Monoclonal antibody directed to fgfr1 |
WO2018129451A2 (en) | 2017-01-09 | 2018-07-12 | Merrimack Pharmaceuticals, Inc. | Anti-fgfr antibodies and methods of use |
EP3624837A1 (de) | 2017-05-16 | 2020-03-25 | Five Prime Therapeutics, Inc. | Anti-fgfr2-antikörper in kombination mit chemotherapeutischen mitteln bei der krebsbehandlung |
EP3444275A1 (de) | 2017-08-16 | 2019-02-20 | Exiris S.r.l. | Monoklonaler antikörper anti-fgfr4 |
JP2024517844A (ja) | 2021-05-04 | 2024-04-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 多重特異性fgf21受容体アゴニスト及びそれらの使用 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4275149A (en) * | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
DE3856559T2 (de) | 1987-05-21 | 2004-04-29 | Micromet Ag | Multifunktionelle Proteine mit vorbestimmter Zielsetzung |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) * | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) * | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
DE69224983T2 (de) * | 1991-01-17 | 1998-07-30 | Univ Washington | Anti-wachstumsfaktor antikörper in der behandlung von gefässstenose |
US6077692A (en) * | 1995-02-14 | 2000-06-20 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 |
RO121900B1 (ro) * | 1996-04-12 | 2008-07-30 | Warner-Lambert Company | Compuşi inhibitori, ireversibili, ai tirozin kinazelor, compoziţie farmaceutică care îi conţine şi utilizarea acestora |
US6486185B1 (en) * | 1997-05-07 | 2002-11-26 | Sugen, Inc. | 3-heteroarylidene-2-indolinone protein kinase inhibitors |
EP1030853A1 (de) * | 1997-11-12 | 2000-08-30 | Ariad Pharmaceuticals, Inc. | Neue inhibitoren von signal-transduction, sie enthaltende zusammensetzungen |
US6514981B1 (en) * | 1998-04-02 | 2003-02-04 | Sugen, Inc. | Methods of modulating tyrosine protein kinase function with indolinone compounds |
US6569868B2 (en) * | 1998-04-16 | 2003-05-27 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
CA2345459A1 (en) * | 1998-11-12 | 2000-05-18 | Regine Bohacek | Bicyclic signal transduction inhibitors, compositions containing them & uses thereof |
UA71971C2 (en) * | 1999-06-04 | 2005-01-17 | Agoron Pharmaceuticals Inc | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases |
TWI262914B (en) * | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
CN1560249A (zh) * | 1999-09-08 | 2005-01-05 | 杰南技术公司 | 成纤维细胞生长因子-19(fgf-19)的核酸和多肽以及用于治疗肥胖的方法 |
US20020150575A1 (en) * | 2000-01-07 | 2002-10-17 | Cook Mark E. | Method to suppress appetite and reduce weight gain |
SK287142B6 (sk) * | 2000-02-15 | 2010-01-07 | Sugen, Inc. | Inhibítory proteínkináz na báze pyrolom substituovaného 2-indolinónu, farmaceutický prípravok s ich obsahom a ich použitie |
EP1268544A2 (de) * | 2000-03-31 | 2003-01-02 | Institut Pasteur | Peptide die das vaskuläre endothelzellen wachstumsfaktor (vegf)-vermittelte angiogenese blockieren, polynukleotide die dafür kodieren und verwendungen davon |
SE0001285D0 (sv) * | 2000-04-07 | 2000-04-07 | Elinus Ab | Djur- och cellmodeller för diabetes typ II och deras användning |
MY128450A (en) * | 2000-05-24 | 2007-02-28 | Upjohn Co | 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
ATE295354T1 (de) * | 2000-08-18 | 2005-05-15 | Agouron Pharma | Heterozyklische-hydroximino-fluorene und ihre verwendung zur inhibierung von proteinkinasen |
WO2002096361A2 (en) * | 2001-05-30 | 2002-12-05 | Sugen, Inc. | 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors |
JP2005500034A (ja) * | 2001-06-20 | 2005-01-06 | プロション バイオテク リミテッド | 受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用 |
AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
CN100531796C (zh) * | 2002-01-31 | 2009-08-26 | 马普科技促进协会 | Fgfr激动剂 |
JP2005535629A (ja) * | 2002-06-27 | 2005-11-24 | ザ ユニバーシティ オブ クイーンズランド | 分化調節薬剤およびその使用法 |
PT1680140E (pt) | 2003-10-16 | 2011-05-31 | Imclone Llc | Inibidores do receptor-1 do factor de crescimento de fibroblastos e m?todos de tratamento destes |
-
2004
- 2004-10-18 PT PT04796034T patent/PT1680140E/pt unknown
- 2004-10-18 JP JP2006535458A patent/JP4686465B2/ja not_active Expired - Fee Related
- 2004-10-18 DE DE602004032370T patent/DE602004032370D1/de active Active
- 2004-10-18 SI SI200431700T patent/SI1680140T1/sl unknown
- 2004-10-18 ES ES04796034T patent/ES2361917T3/es active Active
- 2004-10-18 CA CA002542638A patent/CA2542638A1/en not_active Abandoned
- 2004-10-18 US US10/575,977 patent/US20070274981A1/en not_active Abandoned
- 2004-10-18 AT AT04796034T patent/ATE506077T1/de active
- 2004-10-18 EP EP04796034A patent/EP1680140B1/de not_active Not-in-force
- 2004-10-18 PL PL04796034T patent/PL1680140T3/pl unknown
- 2004-10-18 WO PCT/US2004/034970 patent/WO2005037235A2/en active Application Filing
- 2004-10-18 CA CA2762955A patent/CA2762955A1/en not_active Abandoned
- 2004-10-18 EP EP08020599A patent/EP2060270A3/de not_active Withdrawn
- 2004-10-18 EP EP10162585A patent/EP2229955A1/de not_active Withdrawn
- 2004-10-18 DK DK04796034.9T patent/DK1680140T3/da active
-
2011
- 2011-05-20 CY CY20111100497T patent/CY1111479T1/el unknown
- 2011-12-16 US US13/328,147 patent/US8263074B2/en not_active Expired - Fee Related
Non-Patent Citations (4)
Title |
---|
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; August 2003 (2003-08-01), LI PENG ET AL: "Fibroblast growth factor mediates hypoxia-induced endothelin-A receptor expression in lung artery smooth muscle cells.", XP002540130, Database accession no. PREV200300398597 * |
JOURNAL OF APPLIED PHYSIOLOGY, vol. 95, no. 2, August 2003 (2003-08-01), pages 643 - 651, ISSN: 8750-7587 * |
LI PENG ET AL: "Fibroblast growth factor-1 stimulates endothelin-A receptor expression in pulmonary arterial smooth muscle cells via transcriptional activation", FASEB JOURNAL, vol. 16, no. 5, 22 March 2002 (2002-03-22), & ANNUAL MEETING OF PROFESSIONAL RESEARCH SCIENTISTS ON EXPERIMENTAL BIOLOGY; NEW ORLEANS, LOUISIANA, USA; APRIL 20-24, 2002, pages A1118, XP008109187, ISSN: 0892-6638 * |
PANEK R L ET AL: "IN VITRO BIOLOGICAL CHARACTERIZATION AND ANTIANGIOGENIC EFFECTS OF PD 166866, A SELECTIVE INHIBITOR OF THE FGF-1 RECEPTOR TYROSINE KINASE", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, US, vol. 286, no. 1, 1 January 1998 (1998-01-01), pages 569 - 577, XP008065509, ISSN: 0022-3565 * |
Also Published As
Publication number | Publication date |
---|---|
SI1680140T1 (sl) | 2011-08-31 |
US20120121609A1 (en) | 2012-05-17 |
EP1680140B1 (de) | 2011-04-20 |
US20070274981A1 (en) | 2007-11-29 |
EP2060270A2 (de) | 2009-05-20 |
ATE506077T1 (de) | 2011-05-15 |
US8263074B2 (en) | 2012-09-11 |
WO2005037235A3 (en) | 2005-12-22 |
CA2762955A1 (en) | 2005-04-28 |
EP2229955A1 (de) | 2010-09-22 |
JP4686465B2 (ja) | 2011-05-25 |
EP1680140A2 (de) | 2006-07-19 |
PL1680140T3 (pl) | 2011-11-30 |
ES2361917T3 (es) | 2011-06-24 |
PT1680140E (pt) | 2011-05-31 |
CY1111479T1 (el) | 2015-08-05 |
DE602004032370D1 (de) | 2011-06-01 |
CA2542638A1 (en) | 2005-04-28 |
EP1680140A4 (de) | 2007-12-05 |
JP2008501302A (ja) | 2008-01-24 |
WO2005037235A2 (en) | 2005-04-28 |
DK1680140T3 (da) | 2011-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2060270A3 (de) | Fibroblasten-Wachstumsfaktorrezeptor-1-Inhibitoren und Behandlungsverfahren damit | |
Walker et al. | Nicotinic regulation of c-fos and osteopontin expression in human-derived osteoblast-like cells and human trabecular bone organ culture | |
EP2431050A8 (de) | Verfahren zur Behandlung von Krebs mittels Therapie mit IL-21- und monoklonaler Antikörper | |
EP2281841A3 (de) | Biomarker zur Vorauswahl von Patienten für eine Anti-IGF1R Therapie | |
WO2004037861A3 (en) | Neutralizing antibodies against gdf-8 and uses therefor | |
WO2003027248A8 (en) | Antibody inhibitors of gdf-8 and uses thereof | |
HUE048539T2 (hu) | Eljárás szénhidrogének és oxigéntartalmú vegyületek elõállítására biomasszából, amely eljárás magában foglal fermentációt aminosavak (LEU, ILE, VAL) hozzáadásával | |
WO2003063893A3 (en) | Fgfr agonists | |
ATE478944T1 (de) | Zytokin ligand zur behandlung von asthma und atemwegsüberreaktivität | |
WO2005047331A3 (en) | Antibodies that bind interleukin-4 receptor | |
WO2010065072A8 (en) | Antagonists of il-6 to raise albumin and/or lower crp | |
WO2004009776A3 (en) | TREATMENT OF TNFα RELATED DISORDERS | |
WO2003011213A3 (en) | Method for treating diabetes and obesity | |
EP1582805A3 (de) | Beleuchtungsverfahren und Beleuchtungsapparat, die Reflektoren benutzen | |
EP2412726A3 (de) | Von Metallothionein abgeleitete Peptidfragmente | |
HK1095160A1 (en) | Use of fibroblast growth factor fragments | |
WO2003004637A1 (fr) | Utilisation du gene h3 du recepteur d'histamine participant au controle du poids corporel ou de l'alimentation | |
WO2004033645A3 (en) | Methods of regulating body weight | |
WO2002026193A3 (en) | Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas | |
WO2002074322A3 (en) | Human growth hormone for treating children with abnormal short stature and kits and methods for diagnosing gs protein dysfunctions | |
ATE378061T1 (de) | Neurotrophe faktoren zur behandlung einer dysfunktion peripherer nerven im beckenbereich | |
WO2003079964A3 (en) | Composition for stimulating de novo bone induction | |
WO2003013578A8 (en) | Omoxin agonists and antagonists for use in the treatment of metabolic disorders | |
HK1057392A1 (en) | Method for improving properties of combustion residues produced by combustion plant, and method for treatment of the residues | |
TW200505407A (en) | A novel method for treatment and control of hypertension |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 1680140 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: IMCLONE LLC |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1129204 Country of ref document: HK |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
AKY | No designation fees paid | ||
REG | Reference to a national code |
Ref country code: DE Ref legal event code: 8566 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20100610 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1129204 Country of ref document: HK |